Figure 5. Treatment with anti–IL-17 antibody reduces EV-D68–induced airway responsiveness.
Female 8- to 10-week-old BALB/c mice were treated with sham, 5 × 106 ePFU of EV-D68, or 5 × 106 PFU of RV-A1B alone or in combination with anti–IL-17 antibody or isotype control. Changes in airway resistance to nebulized increasing doses of methacholine were assessed in tracheotomized mice using a Buxco FinePointe plethysmograph. BAL and mRNA analysis was also carried out in similarly treated mice. (A) BAL cell counts for the indicated groups. (B) qPCR analysis of lung mRNA expression. Data are shown as mean ± SEM for 4 mice in each group from a single experiment. *P < 0.05 by ANOVA, compared with RV-1B; †P < 0.05 by ANOVA, compared with IgG. (C) Airway responsiveness to increasing doses of methacholine. n =3–4/group from a single experiment. *P < 0.05 by 2-way ANOVA, compared with sham; †P < 0.05 by 2-way ANOVA, compared with EV-D68 + IgG.